Connect
MJA
MJA

Proton-pump inhibitors and the risk of antibiotic use and hospitalisation for pneumonia

Elizabeth E Roughead, Emmae N Ramsay, Nicole L Pratt, Philip Ryan and Andrew L Gilbert
Med J Aust 2009; 190 (3): 114-116.

Summary

Objective: To determine whether proton-pump inhibitor (PPI) use is associated with hospitalisations for pneumonia and with antibiotic use.

Design and setting: Historical cohort study in the Australian veteran population, conducted from 1 January 2002 to 30 December 2006, comparing veterans exposed to PPIs with those not exposed.

Participants: All 185 533 veterans who were Gold Card holders (ie, eligible for all health services subsidised by the Department of Veterans’ Affairs) and aged 65 years and over at 1 January 2002 and had been prescribed at least one medicine in the previous 6 months.

Main outcome measures: The primary endpoint was hospitalisation for pneumonia. Secondary endpoints included hospitalisation for bacterial pneumonia and dispensings of antibiotics commonly used to treat respiratory tract infections.

Results: After adjustment for potential confounders, we found an increased risk of hospitalisation for pneumonia among those exposed to PPIs compared with the unexposed group (rate ratio [RR], 1.16; 95% CI, 1.11–1.22). The risk was not increased for bacterial pneumonia (RR, 1.13; 95% CI, 0.98–1.31), which made up 8% of pneumonia cases. An increased risk of antibiotic dispensings was observed among those exposed to PPIs (RR, 1.23; 95% CI, 1.21–1.24).

Conclusions: PPI dispensings were found to be associated with a small but significant increased risk of hospitalisation for pneumonia. While the increased risk is small, the prevalent use of PPIs means that many people could be affected.

  • Elizabeth E Roughead1
  • Emmae N Ramsay2
  • Nicole L Pratt2
  • Philip Ryan2
  • Andrew L Gilbert3

  • 1 School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA.
  • 2 Data Management and Analysis Centre, Discipline of Public Health, University of Adelaide, Adelaide, SA.
  • 3 Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute, University of South Australia, Adelaide, SA.


Acknowledgements: 

This research was funded by the Australian Government Department of Veterans’ Affairs as part of the delivery of the Veterans’ Medicines Advice and Therapeutics Education Services (Veterans’ MATES) project.

Competing interests:

None identified.

  • 1. Intercontinental Marketing Services. World Markets. New products and markets fuel growth in 2005. http://www.imshealth.no/web/content/0,3 148,64576068_63872702_70260998_7797451 8,00.html (accessed Dec 2008).
  • 2. Laheij RJ, Van Ijzendoorn MC, Janssen MJ, Jansen JB. Gastric acid-suppressive therapy and community-acquired respiratory infections. Aliment Pharmacol Ther 2003; 18: 847-851.
  • 3. Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292: 1955-1960.
  • 4. Gulmez SE, Holm A, Frederiksen H, et al. Use of proton-pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007; 167: 950-955.
  • 5. Canani RB, Cirillo P, Roggero P, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006; 117: e817-e820.
  • 6. World Health Organization Collaborating Centre for Drug Statistics Methodology. Anatomical therapeutic chemical code classification index with defined daily doses. http://www.whocc.no/atcddd/ (accessed Aug 2008).
  • 7. Australian Government Department of Health and Ageing. Schedule of pharmaceutical benefits. PBS for health professionals. http://www.pbs.gov.au/html/healthpro/home (accessed Aug 2008).
  • 8. World Health Organization. International statistical classification of diseases and related health problems. 10th revision. Geneva: WHO, 2002.
  • 9. Australian Bureau of Statistics. Information paper: census of population and housing — socio-economic indexes for areas, Australia, 2001. Canberra: ABS, 2003. (ABS Cat No. 2039.0.) http://www.abs.gov.au/ausstats/abs@.nsf/allprimarymain features/09D68973F50B8258CA2573F0000DA181? opendocument (accessed Dec 2008).
  • 10. Sloan KL, Sales AE, Liu CF, et al. Construction and characteristics of the RxRisk-V: a VA-adapted pharmacy-based case-mix instrument. Med Care 2003; 41: 761-774.
  • 11. Britt H, Miller GC, Charles J, et al. General practice activity in Australia 2006–07. Canberra: Australian Institute of Health and Welfare, 2008. http://www.aihw.gov.au/publications/index.cfm/title/10574 (accessed Dec 2008).
  • 12. Australian Government Department of Health and Ageing. Australian statistics on medicines 2004-05. Canberra: 2007. http://www.health.gov.au/internet/main/publishing.nsf/Content/pbs-pubs-asm2004-05 (accessed Dec 2008).
  • 13. Skull SA, Andrews RM, Byrnes GB, et al. Hospitalized community-acquired pneumonia in the elderly: an Australian case-cohort study. Epidemiol Infect 2008; Jun 18: 1-9. [Epub ahead of print].
  • 14. Therapeutic Guidelines Ltd. eTG complete. Melbourne: Therapeutic Guidelines, 2008. http://www.tg.org.au/index.php?sectionid=71 (accessed Dec 2008).

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.